Accelerated Stem Cell Senescence in Heart Failure


About this study

The purpose of this study is to study circulating progenitor cells in human subjects with heart failure and before and after LVAD therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18 years or greater
  • Willing and able to sign informed consent
  • Falls into one of the following three categories:
    • Normal control
    • Non-ischemic and ischemic cardiomyopathy with chronic but stable heart failure (NYHA Class II-III) too well for left ventricular assist device (LVAD) implant
    • Advanced non-ischemic and ischemic cardiomyopathy with scheduled LVAD placement and referred for pre-implant right heart catheterization

Exclusion Criteria: 

  • Known hematologic malignancy which would confound interpretation of hematopoietic progenitor cell counts
  • Presence amyloid or other infiltrative heart disease.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Barry Boilson, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer